Hematological Parameters of the Hydrazone, 3-[-2-(I,5-Dimethy-3-oxo-2-Phenyl-2,3-Dihydro-1h-Pyrazol-4-yl) Hydrazilidine]-1,3-Diphenylpropane-1,3-Dione (HPDP) and its Co(II) and Cu(II) Complexes

Abstract

A number of haematological and biochemical parameters exhibit abnormal values as diabetic problems worsen, and the toxic effects of various medications used to treat diabetes have also contributed to these parameter abnormalities. Medicines made using hydrazone are widely regarded as safe medications. The goal of the current study was to assess the effectiveness of 3-[-2-(I,5-Dimethy-3-oxo-2-Phenyl-2,3-Dihydro-1h-Pyrazol-4-yl) Hydrazilidine]-1,3-Diphenylpropane-1,3-Dione (HPDP) and its Co(II) and Cu(II) Complexes representing [Co(PDP)2] and [Cu(HPDP)2Cl2] respectively.  Forty-five albino rats were divided into nine groups: (A) normal control, (B) diabetic rats that were not treated, (C) diabetic rats that were given 200 mg kg–1 b.wt of glibenclamide, and (1A, 1B; 2A, 2B, and 3A, 3B) 200 and 400 mg kg–1 b.wt of HPDP, [Co(PDP)₂] and [Cu(HPDP)₂Cl₂] respectively. Haematological markers were assessed following therapy. Blood glucose levels in the text groups were significantly lower (p≤0.05) than in Group B. When compared to the positive control (Group B), haematological parameters (PVC, RBC, and WBC) significantly (p<0.05) rose in groups 4 and 5. Comparing the results to those of the normal control group revealed similar outcomes. The findings indicate that HPDP and its Co(II) and Cu(II) Complexes are safe and effective in reducing the haematological abnormalities linked to diabetes mellitus; as a result, they may be suggested as a medication for the treatment of diabetes mellitus.